What’s Happening? On June 4, a block deal worth ₹825 crore is expected in Alkem Laboratories, a major Indian pharma company. Who’s Selling? Jayanti Sinha, one of the major shareholders, is planning to sell 1.42% stake in the company. Deal Details: • Deal Value: ₹825 crore • Floor Price: ₹4,850 per share • Discount: 3% lower than the last traded price • Broker: Axis Capital Company Performance (Q4 FY25): • Profit: ₹305.9 crore (up 4.2% YoY) • Revenue: ₹3,143.8 crore (up 7.1% YoY) • EBITDA Margin: Fell to 12.4% from 13.7% (a concern for investors) Management Says: CEO Vikas Gupta expects EBITDA margins to stay stable at 19.5% for FY26, with investments continuing in R&D and new markets. Outlook: Alkem Labs expects high single-digit revenue growth in FY26 and double-digit growth in FY27. What is a Block Deal? A block deal is a large transaction of shares (usually over ₹5 crore) between two parties, done in a single trade to avoid big price fluctuations. Why It Matters: • Shows major shareholder activity • Can impact stock price in the short term • Attracts attention of big investors Keep an eye on Alkem Labs as this deal could affect its market sentiment and stock price movement tomorrow.

#PersonalFinance#StockInNews#FundamentalViews#MacroViews#Miscellaneous

1 like